SPARC: A Potential Prognostic and Therapeutic Target in Pancreatic Cancer.

Research output: Contribution to journalArticle


Pancreatic cancer is a complex and heterogeneous disease that often lacks disease-specific symptoms in early stages. The malignancy is currently the fourth leading cause of cancer-related death in Western countries. In advanced stages, the overall 5-year survival is less than 1% to 2%. Most available treatments lack convincing cost-efficiency determinations and are generally not associated with relevant success rates. Targeting stromal components and stromal depletion is currently becoming an area of extensive research in pancreatic cancer. In this context, a glycoprotein, SPARC (secreted protein acidic and rich in cysteine) appears to play a central role. Still, the role of SPARC in carcinogenesis is controversial because conflicting results have been reported, and the pathways involved in SPARC signaling are not well established. Nonetheless, SPARC is highly expressed in the tumor stroma, principally in peritumoral fibroblasts, and the overexpression of SPARC in this compartment is associated with poorer prognosis. Interestingly, it has been suggested that SPARC present in the tumor stroma could sequester albumin-bound paclitaxel, enhancing the delivery of paclitaxel into the tumor microenvironment. In the present review, we summarize the known associations between SPARC and pancreatic cancer. Moreover, present and future therapies comprising SPARC-targeting are discussed.


Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology
Original languageEnglish
Pages (from-to)1024-1035
Issue number7
Publication statusPublished - 2015
Publication categoryResearch

Related projects

Roland Andersson, DANIEL ANSARI, Monika Bauden, Carlos Urey Chavez, Johannes Byrling, Linus Aronsson, Katarzyna Said Hilmersson, Bodil Andersson & Agata Sasor

Swedish Government Agency for Innovation Systems (Vinnova)

2007/05/15 → …

Project: Research

View all (1)